ReviewDrugs2013

Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.

Nadia Harbeck et al.PubMed ↗Publisher ↗

No numbers read from the abstract.